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Abstract
Background: Ending the global tuberculosis (TB) epidemic requires a focus on treating individuals with latent TB
infection (LTBI) to prevent future cases. Promising trials of shorter regimens have shown them to be effective as
preventative TB treatment, however there is a paucity of data on self-administered treatment completion rates. This
pilot trial assessed treatment completion, adherence, safety and the feasibility of treating LTBI in the UK using a
weekly rifapentine and isoniazid regimen versus daily rifampicin and isoniazid, both self-administered for 12 weeks.
Methods: An open label, randomised, multi-site pilot trial was conducted in London, UK, between March 2015 and
January 2017. Adults between 16 and 65 years with LTBI at two TB clinics who were eligible for and agreed to
preventative therapy were consented and randomised 1:1 to receive either a weekly combination of rifapentine/
isoniazid (‘intervention’) or a daily combination of rifampicin/isoniazid (‘standard’), with both regimens taken for
twelve weeks; treatment was self-administered in both arms. The primary outcome, completion of treatment, was
self-reported, defined as taking more than 90% of prescribed doses and corroborated by pill counts and urine
testing. Adverse events were recorded.
Results: Fifty-two patients were successfully enrolled. In the intervention arm 21 of 27 patients completed
treatment (77.8, 95% confidence interval [CI] 57.7–91.4), compared with 19 of 25 (76.0%, CI 54.9–90.6) in the
standard of care arm. There was a similar adverse effect profile between the two arms.
Conclusion: In this pilot trial, treatment completion was comparable between the weekly rifapentine/isoniazid and
the daily rifampicin/isoniazid regimens. Additionally, the adverse event profile was similar between the two arms.
We conclude that it is safe and feasible to undertake a fully powered trial to determine whether self-administered
weekly treatment is superior/non-inferior compared to current treatment.
Trial registration: The trial was funded by the NIHR, UK and registered with ISRCTN (26/02/2013-No.04379941).
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Keypoints
This pilot trial assessed treatment completion and the
feasibility of treating LTBI in the UK using a weekly rifa-
pentine and isoniazid regimen versus daily rifampicin
and isoniazid, both self-administered for twelve weeks.
Treatment completion was comparable between the two
regimens.
Background
Despite the availability of effective treatment for drug
susceptible tuberculosis (TB), it is estimated that a total
of 1.5 million individuals died of the disease worldwide
in 2018 [1]. In the UK, the majority of TB occurs in mi-
grants, and arises largely through the reactivation of in-
fection acquired overseas [2]. Screening for latent
tuberculosis infection (LTBI) is thus an essential element
of any TB elimination strategy [3].
In 2011, Sterling et al. described a 12-dose weekly regi-
men of rifapentine/isoniazid (3HP) with a relatively low
likelihood of drug-related hepatotoxicity (0.4%) [4]. This
regimen was shown to be non-inferior at preventing the
development of active TB to nine months of isoniazid in
a randomised controlled trial (RCT). Within that trial,
adherence could not be evaluated as patients placed on
the 3HP arm had treatment with directly observed ther-
apy (DOT), but those in the control arm did not. Fur-
thermore, one might expect higher rates of completion
with a shorter 12-dose regimen of 3HP than nine
months of treatment.
In light of the promising results from that RCT [4]
and the absence of RCTs comparing 3HP to the UK
standard of care of daily rifampicin/isoniazid for three
months (3HR), a randomised pilot trial between the two
regimens was designed with self-reported treatment
completion as the primary outcome. We enrolled adults
aged between 16 and 65 years and did not use DOT
(treatment was self-administered). Secondary outcomes
sought to assess adherence to the regimens using an ad-
herence tool (MARS), as well as the frequency with
which adverse events (AEs) were observed in the two
study arms. The results of this trial aim to inform the
feasibility of a larger, fully powered, trial assessing the
non-inferiority of treatment completion on 3HP com-
pared to 3HR.
Methods
Trial design and inclusion criteria
Individuals were recruited from two TB clinics in
London, UK, between March 2015 and January 2017. In-
clusion criteria included age (between 16 and 65 years);
LTBI diagnosis by means of an Interferon Gamma Re-
lease Assay (QuantiFERON®-TB Gold In-Tube or T-
SPOT®.TB) or Tuberculin Skin Test (threshold > 5 mm
irrespective of BCG vaccine status); agreeing to accept
preventive treatment; and provision of informed
consent.
We excluded pregnant and breast-feeding women; per-
sons weighing less than 45 kg;; and individuals unable to
receive study drugs due to allergy, liver disease or any
medical condition contraindicating the use of a rifamy-
cin or isoniazid; individuals who needed concomitant
medications that could not be safely taken with study
drugs and those with HIV infection. For this pilot study,
we were concerned that patients on antiretroviral ther-
apy might have to have their medication changed if there
were randomised to the rifampicin arm due to the drug-
drug interaction.
DOT is not standard of care for LTBI treatment in the
UK. Individuals whose social circumstances would ne-
cessitate enhanced adherence support and DOT - such
as homelessness, history of mental health problems, in-
carceration, or problematic drug use - were also
excluded.
After enrolment, individuals were randomised cen-
trally using Sealed Envelope’s web-based Simple Ran-
domisation Service by a member of the study team in
the recruitment clinic. There was no stratification and
the ratio of individuals in the intervention to standard
care arm was 1:1. Recruited individuals were randomised
to receive either 3HP (weekly) in the intervention arm
or 3HR (daily) in the standard of care arm. Dosing was
weight dependant with patients being weighed at each
visit and dosing adjusted accordingly (see Add-
itional File 1, Appendix 1 for dosing schedule). Both
arms self-administered treatment without direct obser-
vation and recruits were educated on how to take the
medication as well as the main side effects of treatment.
Treatment was initiated following an eligibility assess-
ment at baseline (week 0). Subsequent medication was
dispensed at clinic visits at weeks 2, 4 and 8 following an
adherence and AE check as per the study flow chart
below. Extra visits were possible if a patient presented
with any symptoms related to the study medication or
had a mild derangement of liver function tests (see
below in AEs).
Outcomes assessments
Primary outcome: treatment completion
The primary outcome was the proportion completing
treatment in each arm of the study assessed using self-
report. Treatment completion was defined as taking
more than 90% of the prescribed doses of treatment.
This proportion equates to at least 11 doses for patients
taking the weekly intervention regimen and at least 81
doses for patients in the daily standard of care arm. If a
patient missed a scheduled appointment, the investiga-
tion team tried to contact them within the following
week and so total completion had to occur within 16
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weeks. Additionally, if participants failed to attend two
consecutive appointments, they were considered non-
adherent and to have reached one of the endpoints of
the study.
Adherence data were collected at regular dispensing
clinic visits on weeks 2, 4, 8 and at the end of treatment,
using a standardised questionnaire (see Additional File
1, Appendix 2). Adherence and treatment completion
was self-reported and assessed by face-to-face enquiry,
wherein patients were asked if they had missed any
doses of medication since their last clinic visit and the
number of tablets reportedly missed was recorded.
We asked participants to bring with them, at each
visit, their empty pill packages, which were compared to
the number of pills dispensed at the previous visit. At
each clinic visit, urine colorimetric testing for detecting
isoniazid metabolites and pill count assessment were
used to validate the self-reported intake of tablets. The
urine tests used a commercially available assay (Iso-
screen, GFC Diagnostics Ltd., Oxfordshire, UK). For the
purpose of ascertaining treatment completion, we
intended to use urinary metabolite and pill count assess-
ment to validate self-reported intake of tablets with ei-
ther a negative urine test and/or pills still in a pack
taken as evidence of non-compliance. Otherwise, self-
reports were considered sufficient evidence of outcome.
Secondary outcomes
Mars
A validated medication adherence report scale (MARS™)
was used as an assessment of adherence to explore is
utility in TB adherence trials. This uses five dimensions:
‘I alter the dose’, ‘I forget to use it’, ‘I stop taking it for a
while’, ‘I decide to miss out on a dose’, and ‘I take less
than instructed’, using a five-point Likert scale of ‘al-
ways’, ‘often’, ‘sometimes’, ‘rarely’ and ‘never’, scored one
to five, respectively. An overall score of 20 points or
higher is considered high adherence [5, 6]. (See Add-
itional File 1, Appendix 3 for MARS™ questionnaire.)
Adverse events
Assessment of AEs for both arms was carried out at
clinic visits at weeks 2, 4, 8 and at the end of treatment
at week 12. A final post treatment telephone call was
made 4 weeks after the end of treatment to check that
there had been no further AEs following the last dose of
study medication. AEs were assessed from laboratory
tests, including regular liver function tests (LFTs) for
hepatotoxicity, or from a standardised interview to assess
symptoms. They were recorded and graded (1 to 4) ac-
cording to the Division of AIDS (DAIDS) criteria [7].
The probability of whether the study regimen was re-
lated to any AE was assessed by the prescribing phys-
ician. Following events scoring 3 or more, medication
was stopped; following other AEs, trial medication could
be continued at the discretion of the trial physician. For
full details of AEs and discontinuation rules, see Add-
itional File 1, Appendix 4.
Data collection and statistical analysis
Pseudonymised data were collected on case report forms
(CRFs) at study sites. Data were independently double
entered at the study co-ordinating centre into a pass-
word protected Microsoft Access database. These data
were cross validated and corrections made as required
to ensure data accuracy. Consistency and error checking
was carried out to corroborate the two datasets. An as-
sessment of the distribution of baseline characteristics
between the two study arms was used to determine if
adjustment for confounding was required. Treatment
completion and AEs were described.
Results
A total of 126 eligible subjects were screened for eligibil-
ity and 52 enrolled into the study between March 2015
and January 2017. Of these, 27 (51.9%) subjects were
randomly allocated to the intervention treatment arm
and 25 (48.1%) to the standard treatment arm (see Fig. 1
for recruitment detail).
A comparison of the baseline characteristics of the
two study arms revealed no evidence of major imbalance
(See Table 1).
There were no important differences between the two
arms with respect to baseline biochemistry, haematology
or clinical signs measurements.
Primary outcome
Completion of treatment (defined in the protocol as
more than 90% of doses taken by self-report) was similar
in both arms. In the intervention 3HP arm 21/27 com-
pleted compared with 19/25 in the standard of care arm
of daily 3HR (See Table 2). Considering the lack of evi-
dence of imbalances between the trial arms, we did not
adjust for confounding.
In both arms there was no clinical appointment where
individuals who reported full adherence had pills left
and a negative urine test. There were four individuals,
two in each arm, who reported full adherence and had
pills remaining, but all had positive urine tests indicating
they had at least taken some of their prescribed medica-
tion. In the standard of care arm, two individuals re-
ported full adherence, had no pills remaining, but had
negative urine tests. However, there was a marked dis-
crepancy between the urine test and self-reported full
adherence in the intervention arm. In this group 14
(66.7%) individuals had a negative urine test (see Add-
itional File 1, Appendix 5 for detail). We therefore con-
cluded that the gap between pill intake and testing was
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the most likely explanation and this information was not
used to discount self-reported treatment completion.
Secondary outcomes
Adherence using MARS™ tool
There were only two MARS™ ratings of 19, i.e. below the
score considered to represent high compliance, one in
the standard treatment arm at week two, and one in the
intervention treatment arm at week four.
Adverse events
There were 122 AEs reported during the trial. There
were no serious AEs, as defined by DAIDS criteria as
grade 3 or more, recorded during the trial in either study
arm. The relationship to the study drugs was considered
probable for 25 (20.5%), possibly for 53 (43.4%), unlikely
for 35 (28.7%), not related for seven (5.7%) events and a
further two which were not attributed a relationship.
The 25 AEs that were probably the result of the study
drugs occurred in nine subjects and are documented by
study arm in Table 3 and further details can be seen in
Additional File 1, Appendix 6. No participant developed
active TB during the trial.
Blood testing and hepatoxicity
Haematological and biochemical tests were performed
on subjects throughout the study, with a consideration
as to whether these are outside of the normal range. A
small number of subjects were observed to fall outside
of the normal range for these parameters. Of note are
those with raised ALT and AST during the study. There
were seven subjects- three in the experimental treatment
arm and four in the standard treatment arm that had
clinically significant raised ALT results during the trial.
Fig. 1 Flow diagram of recruitment of individuals to trial, allocation, and outcomes. a: Individuals with latent tuberculosis infection (LTBI) were
recruited from TB clinics who agreed to treatment and met the eligibility criteria. b: Subjects randomised to weekly rifapentine/isoniazid (3HP) or
daily rifampicin/isoniazid (3HR). c: Follow-up at 2, 4, 8, 12 weeks. d: Treatment completion defined as more than 90% of prescribed doses taken
post treatment completion one subject was LFU and another an investigator withdrawal. ** n (%) individuals, per arm, that experienced any AE
likely due to drug, as per investigator decision
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In the experimental treatment arm, one subject had
raised ALT values throughout the trial; the other two
had raised ALTs at one and two measurement points. In
the standard treatment arm, two subjects had raised
ALTs at two measurement points, the other two having
raised ALTs at just one point. These subjects had similar
results for ASTs.
As a result, one participant in the standard treatment
arm was withdrawn by the investigator as they had LFTs
> 3 times ULN (upper limit of normal) and were symp-
tomatic. The remaining participants we able to continue
as their results were within acceptable parameters.
Lessons learned and the data generated are sum-
marised to inform future trials (see Table 4, p.12).
Discussion
This is the first UK based RCT comparing the adherence
of weekly 12-dose 3HP regimen to the UK standard of
care of daily rifampicin/isoniazid for three months
(3HR). Within our open label, randomised, multi-site
pilot study of the two regimens for LTBI, we found that
treatment completion, defined as taking more than 90%
of prescribed doses, was comparable between self-
administered weekly rifapentine/isoniazid regimen and
the UK standard of care regimen of self-administered
daily rifampicin/isoniazid. Furthermore, the frequency
and severity of the AEs of the two regimens was similar.
Previous research has demonstrated that self-
administered 3HP is non-inferior to directly observed
3HP [8]. Treatment completion rates of 3HP are high
when administered using DOT and non-inferior when
compared with longer duration regimens such as isonia-
zid monotherapy over nine months [4, 9, 10]. In this
pilot study, we have shown that a fully powered trial effi-
cacy trial comparing these two self-administered regi-
mens is possible, allowing a determination of whether
the 12 weekly 3HP is superior/non-inferior the UK
standard of care.
This pilot used self report as the primary measure of
adherence with an adherence tool, MARS™, as a second-
ary measure. We had hypothesised based on evidence
that it works in asthma and other chronic conditions
and that if shown to be a good measure of outcomes in
TB, it can provide an alternative outcome measure in fu-
ture trials. Unfortunately, it was not very discriminating
as almost everyone had a high score in the pilot study.
However, we also feel, despite the absence of effect in
our relatively small study, that this merits further explor-
ation in the full trial.
Lessons learned and the data generated in this trial
have contributed to the design of the RID-TB trial [11]
Table 1 Comparison of intervention and standard of care arms for potentially important confounding variables at baseline
Variable Intervention (n = 27) Standard (n = 25)
Demographic
Male (%) 13 (48.2%) 13 (52%)
Age: Mean (range) 38.2 (23–56) 32.5 (17–58)
UK Born 2 (7.4%) 3 (12%)
Lifestyle
Concomitant medication 9 (33.3%) 5 (20%)
Alcohol - current 9 (33.3%) 9 (36%)
Smoking
Current 3 (11.1%) 6 (24.0%)
Ex 2 (7.4%) 3 (12.0%)
Never 22 (88.5%) 16 (64.0%)
Clinical
IGRA positive 24 (88.9%) 24 (96%)
TST positive 3 (11.1%) 1 (4%)
Diabetes 1 (3.7%) 1 (4%)
Immunosuppressant medication 1 (3.7%) –
Table 2 Counts of self-reported adherence and end of trial completion for intervention and standard drug regimen
Metric Intervention 3HP n (proportion) [CI*] Standard 3HR n (proportion) [CI*]
Allocated to group 27 25
Received at least 90% of prescribed doses 21 (0.78) [0.58–0.91] 19 (0.76) [0.55–0.91]
*CI 95% confidence interval
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which will be fully powered to estimate the likelihood of
treatment completion of the two regimens and the rela-
tive safety and efficacy of daily 3HR as compared with
weekly 3HP. Subject to cost-effectiveness analyses,
weekly 3HP regimens could be a useful option in pre-
ventative therapy, especially to improve coverage of pop-
ulations who may require adherence support. People
living with HIV are eligible to take part in the full trial.
However, concurrent medication will be carefully
reviewed to ensure that individuals in need for treatment
that cannot be safely taken together with study drugs
will be excluded.
However, caution is needed in interpreting these re-
sults as this was a pilot study which was not powered to
test equivalence or non-inferiority for any outcome. The
size of the trial means that we were unable to assess the
efficacy of the intervention. In this study we excluded
people with risk factors for potential poor treatment ad-
herence, such as homelessness, problematic drug use,
mental health concerns or history of incarceration.
Therefore, our results will not be generalised to these
populations. One advantage of a weekly regimen is that
it could make treating these patient groups more feasible
as ensuring adherence once a week is less resource in-
tensive than every day.
Finally, treatment completion was defined as complet-
ing 90% of doses taken within 125% of the timeframe of
a normal course of treatment. The simplistic nature of a
percentage threshold may mask substantial heterogen-
eity that could lead to different therapeutic coverages in
different patients. There is little good data regards how
adherence patterns - which can be highly complex [12] -
relate to outcomes and exactly what level of adherence
is optimal for any given regimen is unclear [13–15].
In considering the fully powered trial, other short regi-
mens that have been shown to be effective since the start
of the HALT trial should be considered. For example, a
large trial amongst HIV infected individuals, in an area
with high TB prevalence, showed that a one-month daily
rifapentine plus isoniazid (1HP) daily regimen was non-
inferior to 9 months of isoniazid alone in preventing ac-
tive TB and had fewer AEs. Whilst patients self-
administered treatment under trial conditions, 97% of
those who started 1HP treatment completed it, accord-
ing to self-reported data [16]. This large trial also had a
major limitation due to the potential enrolment of indi-
viduals who may not have LTBI [17] suggesting that fur-
ther trial efficacy data may be needed prior to an
adherence study of 1HP, especially in the light of the
recommendation of expanding 1HP regimens [18].
Conclusion
In the first RCT of its kind in the UK, we demonstrate
similar treatment completion rates between a weekly
Table 3 Subjects experiencing at least one adverse event likely






No 23 20 43
Yes 4 (14.8%) 5 (20.0%) 9
Total 27 25 52





Out of individuals who were eligible (126) many (23) declined to take
part in the study. Anecdotally, this was often because they wanted to
receive treatment ‘as normal’. Much of this may be out of the desire
to reduce the number of times to attend clinic or perceptions that
they were getting something less efficacious or safe.
Individuals were required to attend at weeks 0/2/4/8/12 and have a
telephone consult at week 16
Simplified patient information sheet (PIS) with a plain English
summary Minimise additional follow-up appointments, so
care is as close to the standard of care as possible
Making sure that all recruiting clinicians are well trained and
motivated to recruit and there are dedicated recruitment
nurses in clinics
Qualitative interviews of perceptions of LTBI treatment and of
taking part in clinical trials




6 people were LFU and did not complete the trial. Several were at
the end of treatment and so may well have completed treatment
but did not want to attend their last appointment.
Larger incentive at end of treatment
Qualitative interviews for those LFU
Adherence
checks
The isoniazid metabolite urine test frequently came back as negative
because participants in the weekly dosing arm had taken the tablets
more than 24/48 h before being tested. Participants often took the
medication at a time convenient for them e.g. when they were not
working or at weekends.
Electronic measures of adherence may be more useful,
especially when using a weekly regimen e.g. MEMS cap.
Inclusion
criteria
Initially, inclusion criteria specified a positive IGRA test and did not
include TST. The protocol was subsequently amended to include
both.
Individuals under-served populations with social risk factors for poor
adherence were excluded
As broad as possible to include anyone eligible to have LTBI
treatment in usual clinical practice.
Include under-served populations to generate adherence
data regarding their adherence.
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3HP regimen and the daily 3HR standard of care. We
have also demonstrated the feasibility of undertaking a
randomised controlled trial of the two regimens, pow-
ered to estimate the relative efficacy of the two
regimens.
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